0001209191-21-010733.txt : 20210216 0001209191-21-010733.hdr.sgml : 20210216 20210216162256 ACCESSION NUMBER: 0001209191-21-010733 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanna Bastiano CENTRAL INDEX KEY: 0001829069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 21638950 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-11 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001829069 Sanna Bastiano C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Cell & Genetic Therapies Common Stock 2021-02-11 4 S 0 1469 210.44 D 39081 D Common Stock 2021-02-11 4 S 0 217 211.41 D 38864 D Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $210.44 (range $210.06 to $210.90). Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $211.41 (range $211.17 to $211.50). /s/ Sabrina Yohai, Attorney-in-Fact 2021-02-16